Abstract
Biosimilar medicines already on the market may have a primary structure identical to their reference products (e.g., amino acid sequences should be identical). In the case of monoclonal antibodies (mAbs), and due to their more complex structure, a greater level of demand would be in order and identity at other levels (e.g., post-translational modifications within the Fc region of the molecule) should be proved to establish “similarity”. These requirements would lead to a greater development in the process and tighter quality controls during the production of biosimilar mAbs.
The following issues should be taken into account in the comparability exercise:
- The designs of the studies carried out to obtain approval of the reference product are not always adequate to show that safety and efficacy of the biosimilar mAbs are comparable. A similar efficacy does not necessarily imply a similar safety profile between the innovator and biosimilar products.
- The design of clinical tests to demonstrate comparability must be flexible and adaptable throughout the development of the product.
- The European Medicines Agency (EMA) will consider suitable goals in the evaluation of biosimilar mAbs for their approval (e.g., to specify whether their goal is to check similarity with the reference product or to show that the treatment is effective at a clinical level).
Keywords: Biopharmaceuticals, biosimilars, comparability, european guidelines, glycosilation, immunogenicity, monoclonal antibodies (mabs), post-translational modifications, THERAPEUTIC, clinical.
Current Medicinal Chemistry
Title:Therapeutic Monoclonal Antibodies: Strategies and Challenges for Biosimilars Development
Volume: 19 Issue: 26
Author(s): Begona Calvo and Leyre Zuniga
Affiliation:
Keywords: Biopharmaceuticals, biosimilars, comparability, european guidelines, glycosilation, immunogenicity, monoclonal antibodies (mabs), post-translational modifications, THERAPEUTIC, clinical.
Abstract: Biosimilar medicines already on the market may have a primary structure identical to their reference products (e.g., amino acid sequences should be identical). In the case of monoclonal antibodies (mAbs), and due to their more complex structure, a greater level of demand would be in order and identity at other levels (e.g., post-translational modifications within the Fc region of the molecule) should be proved to establish “similarity”. These requirements would lead to a greater development in the process and tighter quality controls during the production of biosimilar mAbs.
The following issues should be taken into account in the comparability exercise:
- The designs of the studies carried out to obtain approval of the reference product are not always adequate to show that safety and efficacy of the biosimilar mAbs are comparable. A similar efficacy does not necessarily imply a similar safety profile between the innovator and biosimilar products.
- The design of clinical tests to demonstrate comparability must be flexible and adaptable throughout the development of the product.
- The European Medicines Agency (EMA) will consider suitable goals in the evaluation of biosimilar mAbs for their approval (e.g., to specify whether their goal is to check similarity with the reference product or to show that the treatment is effective at a clinical level).
Export Options
About this article
Cite this article as:
Calvo Begona and Zuniga Leyre, Therapeutic Monoclonal Antibodies: Strategies and Challenges for Biosimilars Development, Current Medicinal Chemistry 2012; 19 (26) . https://dx.doi.org/10.2174/092986712803251485
DOI https://dx.doi.org/10.2174/092986712803251485 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Corticotropin Releasing Factor (CRF) Peptide Family and their Receptors: Divergent Actions Influencing Human Physiology
Current Genomics Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Proteome Analysis of Formalin-Fixed Paraffin-Embedded Tissues from a Primary Gastric Melanoma and its Meningeal Metastasis: A Case Report
Current Topics in Medicinal Chemistry Self-Reported Physical Complaints are Reduced Upon Regular Use of an In-Home Water Filter System (AcalaQuell®): A Prospective, Controlled, Documentation Study
The Natural Products Journal NGF and BDNF Alterations by Prenatal Alcohol Exposure
Current Neuropharmacology Structural and Bioactive Properties of 3-O-Methylfunicone
Mini-Reviews in Medicinal Chemistry Development of a High Throughput Drug Screening Assay for the Detection of Changes in Tau Levels - Proof of Concept with HSP90 inhibitors
Current Alzheimer Research Artificial Virus as Trump-card to Resolve Exigencies in Targeted Gene Delivery
Mini-Reviews in Medicinal Chemistry General Aspects of Metal Toxicity
Current Medicinal Chemistry Methotrexate Induced Pneumonitis: A Review Article
Current Respiratory Medicine Reviews Studies on Growth Kinetics of Serratia marcescens VITSD2 and Optimization of Fermentation Conditions for Serratiopeptidase Production
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Ameliorative Effect of α-Tocopherol and Selenium on Effects of Malathion on Plasmatic Biochemical Indices and Lesions in the Liver of Rats
Current Pharmaceutical Analysis Telomerase Inhibitors: Potential Anticancer Agents
Mini-Reviews in Organic Chemistry Application of MALDI/SELDI Mass Spectrometry to Cancer Biomarker Discovery and Validation
Current Proteomics Histopathology of Ductal Carcinoma in Situ (DCIS) of the Breast
Current Cancer Therapy Reviews Serum Cytokine Profile in Alzheimer's Disease Patients After Ingestion of an Antioxidant Beverage
CNS & Neurological Disorders - Drug Targets Anti-Hormonal Therapies for Premenopausal Patients – What did we Learn from the TEXT/SOFT Trials?
Reviews on Recent Clinical Trials Therapeutic Potential, Synthesis, Patent Evaluation and SAR Studies of Thieno[3,2-d]pyrimidine Derivatives: Recent Updates
Current Drug Targets The Influence of Cox-2 and Bioactive Lipids on Hematological Cancers
Current Angiogenesis (Discontinued) Synthesis and Anticancer Properties of Novel Truncated Carbocyclic Nucleoside Analogues
Anti-Cancer Agents in Medicinal Chemistry